In honor of Women in Science Day, the Pediatric Cancer Research Foundation would like to proudly recognize some of the brilliant women funded by PCRF who are leading the way in their fields and working to cure pediatric cancer.

Take a look at some of the women who are making a difference and changing the futures of kids fighting pediatric cancer.

Dr. Kathleen Sakamoto – Lucile Packard Children’s Hospital Stanford

Dr. Sakamoto’s goal at Lucile Packard Children’s Hospital Stanford is to bring new drugs to children with relapsed acute leukemia. She is making progress not only in understanding how these new drugs work but also studying how to best use these drugs in patients. Her hope is to improve the overall survival of children with relapsed leukemia so that they will live healthy and productive lives.

Dr. Amanda Saratsis – Ann & Robert Lurie Children’s Hospital

Dr. Saratsis hopes to bring new therapies to clinical trials and improve outcomes for patients with pediatric brain tumors. Initial research will focus on pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine glioma (DIPG). Children affected by these tumors are in dire need of improved treatment options and outcomes.

It has already gained global attention due to the initial findings from the project and the work will be accelerated through generous philanthropic support from the Pediatric Cancer Research Foundation.

New 2020 Researchers

Dr. Eugenie Kleinerman – MD Anderson Cancer Center
Dr. Kleinerman’s research focuses on the development of novel therapies for children with sarcomas, particularly osteosarcoma lung metastases. Osteosarcoma (OS) is the most common primary malignant bone tumor in children, adolescents, and young adults. Altering chemotherapy, including dose intensification, has not improved the 65% survival rate for children, adolescents and young adults (AYAs) with osteosarcoma. The survival for patients with metastases and those that relapse after chemotherapy is less than 20%. Identifying new therapies is imperative. Funding provided by the Pediatric Cancer Research Foundation will support Drs. Kleinerman and Watowich investigate whether a unique molecularly engineered DC vaccine that augments T-cells is effective against primary and metastatic OS using preclinical mouse models and whether its activity can be augmented when combined with checkpoint inhibitors.

Dr. Jana Ellegast – Dana-Farber Cancer Institute
Dr. Ellegast’s is focused on new research that has the potential to offer effective targeted therapies for children facing AML. Leukemia is the most common type of childhood cancer and the second most common cause of cancer-related mortality in children. Treatment options are often limited, particularly for children with acute myeloid leukemia (AML). The laboratory at the Dana-Farber Cancer Institute specializes in discovering new lead compounds and protein targets for cancer therapy. This work will be crucial to the development of selective inhibitors and ultimately enable us to bring these new medicines to children with AML.

The Pediatric Cancer Research Foundation is proud to fund these Women in Science. These are just some of the amazing researchers focused on putting your generous donations to work in 2020. You can help us fight cancer with research.